Open Access iconOpen Access

REVIEW

crossmark

Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

DHANYA K. NAMBIAR1, DEEPALI MISHRA2, RANA P. SINGH2,3,*

1 Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA
2 Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India
3 Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, 10067, India

* Corresponding Author: RANA P. SINGH. Email: email

Oncology Research 2023, 31(4), 405-421. https://doi.org/10.32604/or.2023.028310

Abstract

Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical applications. We focused on the use of PARP inhibitors in various cancers, including prostate cancer. We also discussed some of the underlying principles and challenges that may affect the clinical efficacy of PARP inhibitors.

Graphical Abstract

Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

Keywords


Cite This Article

APA Style
NAMBIAR, D.K., MISHRA, D., SINGH, R.P. (2023). Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials. Oncology Research, 31(4), 405-421. https://doi.org/10.32604/or.2023.028310
Vancouver Style
NAMBIAR DK, MISHRA D, SINGH RP. Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials. Oncol Res. 2023;31(4):405-421 https://doi.org/10.32604/or.2023.028310
IEEE Style
D.K. NAMBIAR, D. MISHRA, and R.P. SINGH "Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials," Oncol. Res., vol. 31, no. 4, pp. 405-421. 2023. https://doi.org/10.32604/or.2023.028310



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1519

    View

  • 793

    Download

  • 0

    Like

Share Link